PT Merck (MERK) Fundamentals 2026 — P/E 6.1x, Revenue Analysis | SniperIQ
PT Merck (MERK) is a ID-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of Rp1.79T, trading at Rp4000.00 on the JKT. This SniperIQ fundamentals page covers PT Merck's valuation (P/E 6.1x, P/B 1.7x), profitability (net margin 23.3%), revenue (Rp1.20T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Merck's market cap?
PT Merck (MERK) has a market capitalization of approximately Rp1.79T, trading at Rp4000.00 on the JKT. Market cap moves with the live share price.
What is PT Merck's P/E ratio?
PT Merck's trailing twelve-month P/E ratio is 6.1x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Merck?
PT Merck runs a net profit margin of 23.3%, a gross margin of 48.7%, and an operating margin of 31.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Merck generate?
PT Merck reported revenue of Rp1.20T for fiscal year 2025, with net income of Rp243.9B and earnings per share (EPS) of 544.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Merck pay a dividend?
PT Merck offers a trailing dividend yield of about 6.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Merck financially healthy?
PT Merck carries a debt-to-equity ratio of 0.02x and a current ratio of 4.91x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Merck a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Merck (MERK) the key facts are: market cap Rp1.79T, P/E 6.1x, revenue Rp1.20T, 52-week range 2720-4500. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Merck's full fundamentals live
Get PT Merck's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.